Application of MultiStem® Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease
Authors:
Open Access
- 1 January 2012
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 3, 33907
Abstract
The last decade has seen much progress in adjunctive cell therapy for immune disorders. Both corporate and institutional Phase III studies have been run using mesenchymal stromal cells (MSC) for treatment of Graft versus Host Disease (GvHD), and product approval has been achieved for treatment of pediatric GvHD in Canada and New Zealand (Prochymal®; Osiris Therapeutics). This effectiveness has prompted the prophylactic use of adherent stem cells at the time of allogeneic hematopoietic stem cell transplantation (HSCT) to prevent occurrence of GvHD and possibly provide stromal support for hematopoietic recovery. The MultiStem® product is an adult adherent stem cell product derived from bone marrow which has significant clinical exposure. MultiStem cells are currently in phase II clinical studies for treatment of ischemic stroke and ulcerative colitis, with Phase I studies completed in acute myocardial infarction and for GvHD prophylaxis in allogeneic HSCT, demonstrating that MultiStem administration was well tolerated while the incidence and severity of GvHD was reduced. In advancing this clinical approach, it is important to recognize that alternate models exist based on clinical manufacturing strategies. Corporate sponsors exploit the universal donor properties of adherent stem cells and manufacture at large scale, with many products obtained from one or limited donors and used across many patients. In Europe, institutional sponsors often produce allogeneic product in a patient designated context. For this approach, disposable bioreactors producing <10 products/donor in a closed system manner are very well suited. In this review, the use of adherent stem cells for GvHD prophylaxis is summarized and the suitability of disposable bioreactors for MultiStem production is presented, with an emphasis on quality control parameters, which are critical with a multiple donor approach for manufacturing.Keywords
This publication has 50 references indexed in Scilit:
- Editorial: Our Top 10 Developments in Stem Cell Biology over the Last 30 YearsStem Cells, 2011
- Clinical trials for stem cell therapiesBMC Medicine, 2011
- Regenerative Stromal Cell Therapy in Allogeneic Hematopoietic Stem Cell Transplantation: Current Impact and Future DirectionsTransplantation and Cellular Therapy, 2010
- Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantationBone Marrow Transplantation, 2010
- Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell.2009
- Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trialBone Marrow Transplantation, 2008
- Potential role of mesenchymal stromal cells in pediatric hematopoietic SCTBone Marrow Transplantation, 2008
- Multipotent adult progenitor cells sustain function of ischemic limbs in miceJournal of Clinical Investigation, 2008
- Defining embryonic stem cell identity using differentiation-related microRNAs and their potential targetsMammalian Genome, 2007
- Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy PatientsTransplantation and Cellular Therapy, 2005